How Does Semaglutide Work in the Body?
Semaglutide is a lab-made copy of the gut hormone GLP-1 that binds GLP-1 receptors to stimulate insulin, lower glucagon, slow stomach emptying, and reduce appetite in the brain. Three chemical changes give it a half-life of about one week, so one injection lasts seven days.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Semaglutide works by copying a hormone your gut already makes. After you eat, cells in the intestine release GLP-1, which tells the pancreas to release insulin, holds back glucagon, slows the stomach, and signals the brain to cut appetite. Semaglutide is a GLP-1 analog with 94% sequence homology to human GLP-1, and it selectively binds to and activates the same GLP-1 receptor that native GLP-1 targets [1]. It lowers blood sugar in a glucose-dependent way, meaning it pushes insulin up and glucagon down mainly when blood sugar is high [1]. It also delays early stomach emptying after meals [1] and acts on brain regions that control appetite [5, 6].
It lasts a week because of three deliberate chemical changes. One shields the molecule from DPP-4, the enzyme that destroys natural GLP-1 within minutes. Another lets semaglutide attach to albumin, a blood protein, which slows its clearance and protects it from breakdown [1]. A third makes sure only one attachment point is used [1]. The result is an elimination half-life of about one week [1, 6].
What kind of drug is semaglutide?
Semaglutide is a GLP-1 receptor agonist, also called a GLP-1 analog. It is a peptide whose backbone is produced by yeast fermentation [1]. As a medicine it comes as Ozempic, a subcutaneous injection given once weekly [1], and as Rybelsus and Ozempic tablets, taken orally once daily [13]. The injection and the tablets are not substitutable on a mg-to-mg basis [13].
How is semaglutide different from the GLP-1 your body makes?
Natural GLP-1 comes from the gut, from intestinal L cells, not the pancreas [9, 10]. After a meal it stimulates insulin, inhibits glucagon, and also inhibits food intake and gastric emptying [9]. The problem is that it does not survive long. The circulating half-life of native GLP-1 is only 1.5–2 minutes in people with diabetes [9]. An enzyme called DPP-4 cleaves GLP-1 between Ala8 and Glu9, and only about 10–20% of the GLP-1 in plasma stays in its active form [10].
Semaglutide keeps the same job but resists that breakdown. Here is how the two compare:
| Native GLP-1 | Semaglutide | |
|---|---|---|
| Sequence | Human hormone | 94% homology to human GLP-1 [1] |
| DPP-4 breakdown | Cleaved rapidly; only 10–20% stays active [10] | Stabilized against DPP-4 [1] |
| Half-life | 1.5–2 minutes in people with diabetes [9] | About 1 week [1, 6] |
| Dosing | Released by the gut in response to meals [9] | Injection once weekly [1]; tablets once daily [13] |
What was changed in the molecule?
Three changes turn a minutes-long hormone into a week-long drug. At position 8, an amino acid called Aib replaces alanine, which stabilizes the molecule against DPP-4 [1, 10]. At position 26, a lysine carries a hydrophilic spacer and a C18 fatty diacid, which is what lets semaglutide bind to albumin in the blood [1]. A minor change at position 34 makes sure only one fatty diacid attaches [1].
Why does one dose last a week?
Albumin binding is the main reason. Semaglutide is extensively bound to plasma albumin, at more than 99% [1]. That binding decreases renal clearance and protects the drug from metabolic degradation [1]. The elimination half-life is approximately 1 week, about 160 hours, compared with roughly 12 hours for liraglutide, an older GLP-1 drug that is dosed once daily [1, 6, 10].
With weekly dosing, steady-state exposure is reached after 4 to 5 weeks, and semaglutide is still present in the circulation about 5 weeks after the last dose [1]. The body clears it mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain, and about 3% of the dose is excreted in the urine as intact semaglutide [1].
How does semaglutide lower blood sugar?
In the pancreas, semaglutide stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. When blood sugar is high, insulin secretion is stimulated and glucagon is inhibited [1]. Inside the cells, GLP-1 receptor signaling works through the Gs protein, adenylate cyclase, and cyclic AMP, which then activates PKA and Epac2 pathways to drive glucose-dependent insulin release [10].
In a 12-week study of people with type 2 diabetes taking semaglutide 1 mg versus placebo, fasting glucose fell by 29 mg/dL (22%), 2-hour postprandial glucose fell by 74 mg/dL (36%), and mean 24-hour glucose fell by 30 mg/dL [1]. Both first- and second-phase insulin secretion increased, fasting glucagon fell 8%, and the postprandial glucagon response fell 14 to 15% compared with placebo [1].
During experimentally induced hypoglycemia, semaglutide did not alter the counter-regulatory glucagon response [1]. The label still warns that the risk of hypoglycemia, including severe hypoglycemia, goes up when semaglutide is used together with insulin or an insulin secretagogue, and that reducing the dose of those other drugs may be necessary [1].
Does Ozempic slow your stomach?
Yes, by a modest amount early after meals. The label states that semaglutide causes a delay of early postprandial gastric emptying, which reduces the rate at which glucose appears in the circulation after eating [1]. Because of this, delayed gastric emptying may affect the absorption of other oral medications taken at the same time [1].
Two trials have measured this, in different groups and at different doses. A 12-week study of semaglutide 1.0 mg in people with obesity showed a delay in first-hour gastric emptying [3]. Separately, in the Friedrichsen trial of semaglutide 2.4 mg, an indirect measure using acetaminophen absorption at week 20 showed only an 8% increase in the 0–5 hour acetaminophen AUC, which was not significant after correction for body weight, and no effect on the first-hour measure [3]. That was one indirect test at one time point in one trial, not proof that the stomach plays no role.
The label also reports that pulmonary aspiration during general anesthesia or deep sedation has occurred in patients receiving GLP-1 receptor agonists undergoing elective procedures, and it instructs patients to tell their healthcare providers about any planned surgeries or procedures [1].
Why does Ozempic make you feel full and eat less?
The clearest human evidence comes from the Friedrichsen trial: 72 adults with obesity, randomized and treated for 20 weeks with weekly semaglutide escalated to 2.4 mg or placebo [3]. At a lunch where participants could eat freely, energy intake was 35% lower with semaglutide: 1736 kJ versus 2676 kJ, a difference of 940 kJ [3]. Participants reported less hunger and prospective food consumption, more fullness and satiety, better control of eating, and fewer and weaker food cravings [3]. Body weight fell 9.9% with semaglutide versus 0.4% with placebo [3].
A review in The American Journal of Medicine describes the weight-loss mechanism as partly central, acting on brain regions that control appetite, and partly peripheral, acting on insulin secretion, glucagon release, gastric emptying, and gut hormones [5].
Does semaglutide cross the blood-brain barrier?
In rodents, no. A research team found that semaglutide did not cross the blood-brain barrier. Instead, it reached the brain through the circumventricular organs, small structures where the barrier is absent, and through select sites adjacent to the ventricles [6]. The circumventricular organs it reached included the area postrema, the median eminence, the vascular organ of the lamina terminalis, and the subfornical organ [6]. It also directly accessed the brainstem, the septal nucleus, and the hypothalamus, and directly activated arcuate POMC/CART neurons [6].
That rodent work showed semaglutide inducing c-Fos activation, a marker of neuronal activity, in 10 brain areas, including the lateral parabrachial nucleus, a region tied to meal termination [6]. The animals ate less, changed food preference, and lost weight without a decrease in energy expenditure [6]. The authors concluded that the weight effect comes from diverse GLP-1 receptor populations acting through multiple neural pathways [6]. These findings are from rodent research.
Where in the brain does semaglutide act?
A 2026 study in Nature Metabolism identified the area postrema as the primary site of semaglutide action in the brain [8]. It found that semaglutide engages both Gs- and Gq-dependent signaling, and drives graded increases in cyclic AMP through the Gs pathway in area postrema Glp1r neurons [8]. When the researchers disrupted Gs or cAMP signaling in those neurons, semaglutide-induced weight loss was abolished [8].
Why do the doses start low and go up?
The most common adverse reactions reported in at least 5% of patients are nausea, vomiting, diarrhea, abdominal pain, and constipation [1]. The Ozempic injection label starts treatment at 0.25 mg once weekly for 4 weeks and then escalates the dose, and it states that this escalation is used to reduce the risk of gastrointestinal adverse reactions [1]. The tablet labels follow the same logic: Rybelsus starts at 3 mg daily and Ozempic tablets at 1.5 mg daily for 30 days, and both labels state that these starting doses are not effective for glycemic control [13]. Ozempic is not recommended in patients with severe gastroparesis [1].
Does the weight you lose come from fat or muscle?
A STEP 1 substudy measured this directly. It followed 140 participants with dual energy X-ray absorptiometry (DEXA) scans at screening and week 68 while they took semaglutide 2.4 mg or placebo [12]. Body weight fell 15.0% with semaglutide versus 3.6% with placebo [12]. Total fat mass fell 19.3% and regional visceral fat fell 27.4%, while total lean body mass fell 9.7% [12].
Because fat fell faster than lean mass, the proportion of body mass made up of lean tissue actually rose by 3.0 percentage points, and the lean-to-fat ratio improved most in people who lost 15% or more of their body weight [12].
Sources
- National Library of Medicine DailyMed. OZEMPIC (semaglutide) injection, solution. Drug label.
- US Food and Drug Administration. OZEMPIC (semaglutide) injection prescribing information. 2026.
- Diabetes, Obesity and Metabolism. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. 2021.
- Diabetes, Obesity and Metabolism. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. March 2018.
- The American Journal of Medicine. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. June 2025.
- JCI Insight. Semaglutide lowers body weight in rodents via distributed neural pathways.
- Cell Metabolism. Semaglutide effects on energy balance are mediated by Adcyap1+ neurons in the dorsal vagal complex.
- Nature Metabolism. Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons.
- Journal of Clinical Investigation. Discovery, characterization, and clinical development of the glucagon-like peptides.
- Nutrition & Diabetes. Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.
- FEBS Letters. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. January 30, 1995.
- PubMed Central. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.
- National Library of Medicine DailyMed. RYBELSUS (oral semaglutide) tablet. Drug label.
Frequently asked questions
Does semaglutide cross the blood-brain barrier?
In rodent research, semaglutide did not cross the blood-brain barrier. It reached the brain through the circumventricular organs, including the area postrema, and select sites adjacent to the ventricles, where it directly accessed the brainstem, septal nucleus, and hypothalamus. These findings come from rodent research.
Does Ozempic slow stomach emptying?
Yes. The label states that semaglutide causes a delay of early postprandial gastric emptying, which reduces the rate at which glucose appears in the circulation after meals, and that this may affect absorption of other oral medications. In one 20-week trial at 2.4 mg, an indirect acetaminophen-absorption measure at week 20 showed only an 8% difference that lost significance after body-weight correction.
Why does Ozempic make you feel full?
Semaglutide acts on brain regions that control appetite and on the stomach, delaying early gastric emptying [1, 5]. In a 20-week trial, people taking semaglutide 2.4 mg ate 35% less at a free-choice lunch, reported less hunger, more fullness and satiety, and fewer and weaker food cravings than those on placebo.
How long does semaglutide stay in the body after the last dose?
Semaglutide has an elimination half-life of about one week, and it remains in the circulation for about 5 weeks after the last dose. Steady-state levels are reached after 4 to 5 weeks of once-weekly dosing. The label cites this long washout period as the reason to stop the drug at least 2 months before a planned pregnancy.
Why does the dose start low and increase?
The Ozempic label starts injections at 0.25 mg once weekly for 4 weeks and then escalates, stating that this schedule is used to reduce the risk of gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, abdominal pain, and constipation. The tablet labels similarly start low, and state that the starting doses are not effective for glycemic control.
Can semaglutide cause low blood sugar?
Semaglutide stimulates insulin and lowers glucagon only in a glucose-dependent manner, so when blood sugar is normal or low, the effect tapers. However, the label warns that using it with insulin or an insulin secretagogue can increase the risk of hypoglycemia, including severe hypoglycemia, and that reducing the dose of those drugs may be necessary.
Does semaglutide cause muscle loss?
In a STEP 1 substudy of 140 people, semaglutide 2.4 mg cut total fat mass by 19.3% and regional visceral fat by 27.4%, while total lean body mass fell 9.7% over 68 weeks. Because fat fell faster than lean mass, the lean share of total body mass rose by 3.0 percentage points.
How is semaglutide different from the body's own GLP-1?
Native GLP-1 from the gut lasts only 1.5–2 minutes in people with diabetes because DPP-4 rapidly breaks it down, leaving only about 10–20% active in plasma [9, 10]. Semaglutide has 94% sequence homology to human GLP-1 but is stabilized against DPP-4 and binds albumin at more than 99%, giving it a half-life of about one week.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.